Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Other Non Operating Income (2019 - 2025)

Inmune Bio's Other Non Operating Income history spans 5 years, with the latest figure at $166000.0 for Q1 2025.

  • For Q1 2025, Other Non Operating Income rose 2175.0% year-over-year to $166000.0; the TTM value through Mar 2025 reached $214915.0, up 41.95%, while the annual FY2024 figure was $553000.0, 307.12% up from the prior year.
  • Other Non Operating Income for Q1 2025 was $166000.0 at Inmune Bio, up from -$8000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $166000.0 in Q1 2025 and bottomed at -$8000.0 in Q1 2021.
  • The 3-year median for Other Non Operating Income is -$8000.0 (2021), against an average of $50000.0.
  • The largest annual shift saw Other Non Operating Income crashed 136.36% in 2021 before it surged 2175.0% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at -$8000.0 in 2021, then changed by 0.0% to -$8000.0 in 2024, then soared by 2175.0% to $166000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Other Non Operating Income are $166000.0 (Q1 2025), -$8000.0 (Q1 2024), and -$8000.0 (Q1 2021).